Portfolio companies

www.impulse-dynamics.com

Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF), based on its proprietary technology for administrating Cardiac Contractility Modulation (CCM) therapy. CCM has been shown in clinical trials to produce an immediate and powerful effect, resulting in a significant increase in cardiac performance, thereby improving exercise tolerance. Trials have also indicated its safety and its role in significantly improving quality of life. Impulse Dynamics’ Optimizer IVs is CE marked and has been successfully launched in Europe and other international markets. The device has been implanted in around 3,000 patients to date, with some receiving the therapy for over 10 years. The Optimizer IVs is currently undergoing the final stages of clinical evaluation to support FDA approval.

www.MetaCure.com

MetaCure is a medical device company dedicated to the development and commercialization of a minimally-invasive treatment for type 2 diabetes, arguably today’s most prevalent global health epidemic. MetaCure’s implantable medical device, the DIAMOND, is based on an innovative technology that significantly reduces blood glucose levels by applying gentle electrical stimulation to the stomach during meals. The DIAMOND has the potential to be a preferred treatment option for patients who are otherwise considered for injectable therapies. Over 300 patients have been implanted with DIAMOND in clinical trials in Europe, the US and Asia, with follow-up data for up to 10 years showing that the system is well-tolerated. The DIAMOND may reduce HbA1c by up to 2.5% (avg. 1% – 1.5%), with a sustained effect for at least three years. Patients may also benefit from weight loss (avg. 5 – 8 kg).

www.Motorika.com

Motorika develops and commercializes robot-assisted solutions to meet the therapeutic needs of patients suffering from variety of neurological conditions, including stroke, traumatic brain injury and spinal cord injury, as well as orthopedic and post-surgery dysfunction. Since its inception, the company has become established as a leader in the development and marketing of innovative, high-end, robotic rehabilitation products for the upper and lower extremities. Reo, the company’s flagship product family, actively engages patients’ neuromuscular re-education through intensive, repetitive, task-specific exercises in various robotic modes with instant augmented feedback. Reo improves upper and lower limb function, accelerates motor and cognitive recovery and provides improved clinical outcomes through a combination of a wide variety of movements and intense repetition. Motorika works with top experts in the field of Rehabilitation Medicine to develop high-level products that are flexible, easy-to-use and customized to each patient’s unique needs.

www.flowmedic.com

FlowMedic has developed innovative miniaturized portable leg compression devices for the treatment of PAD and prevention of DVT. Incorporating proprietary technology, these portable compression devices offer continuous treatment to surgical patients, from the start of the surgery, during hospitalization and continuing as prophylactic treatment at home, offering a safe and effective alternative to anticoagulant drugs. FlowMedic’s FM220 employs an ingenious, patent-protected mechanism of infrequent high-intensity compressions, with minimum power consumption needs and no inconvenience to the patient. The FM220 provides a high degree of compression, both eliminating clotting and improving circulation in patients with PAD. FlowMedic’s Homefit system offers a simple portable compression device that improves circulation, and prevents blood clotting and DVT.

www.molecular-d.com

Molecular Dynamics develops innovative imaging technologies and advanced clinical applications. The company’s whole-body functional imaging system, based on CZT technology, simultaneously improves image quality, scan time and patient dose. The scanner delivers better-than-PET quality images, with an attractive wide-band, multi-function imaging ability not possible with current PET scanners. The company aims to enable improved diagnosis, treatment-optimization and monitoring, resulting in more cost-effective treatments and better clinical outcomes.

www.Renal-Dynamics.com

Renal Dynamics (ReDy) is dedicated to treating hypertension with a single intervention, using its third-generation renal denervation system. ReDy’s proprietary solution uses the SmartRF algorithm to optimize bipolar and unipolar energy delivery and to confirm lesion formation. The system uses an advanced product design, intended to improve usability by the operator, shorten procedure time and improve patient comfort. The ReDy system has obtained CE mark and is currently being validated in clinical trials.

www.epd-medical.com

EP Dynamics (EPD) is dedicated to improving the efficacy and efficiency of minimally-invasive catheter-based procedures performed to treat cardiac arrhythmias. A proprietary dielectric-based platform, which is currently under development, will enable the measurement of the permanency, transmurality and continuity of cardiac AF ablation lesions, thereby significantly improving the efficacy of AF ablation. The platform also provides an estimated ablation depth, reports catheter contact quality, and gives an accurate 3D localization of EP catheters.

OncoD is an early-stage company seeking to improve the treatment of cancer by simplifying image-guided solid-tumor ablation procedures. OncoD is currently developing a set of interventional radiology imaging tools which aim to improve clinical outcomes and shorten procedure time through hyper-reality visualization, real-time accurate monitoring of treatment effects and patient-specific pre-planning and procedure guidance. These will provide high-definition mapping and navigation capabilities outside of the imaging suite and without radiating computed tomography (CT) or expensive magnetic resonance imaging (MRI) devices. The optimized graphic user interface will lower the dependency on physician experience and shorten learning curves, making the procedure and its clinical benefits widely available for cancer patients globally.

Lavita Technologies is an early-stage neuromodulation company, focused on development of the proprietary Nexion™ system for treatment of autoimmune inflammatory diseases caused by an overactive sympathetic nervous system. This breakthrough technology has a wide range of applications, including rheumatoid arthritis, inflammatory bowel disease, and metabolic disorders. The Nexion™ system utilizes a catheter-based percutaneous approach to deliver targeted and localized energy to modulate and reset nerve activities specific to the inflammation.

Public and acquired companies

NovoCure’s Tumor Treating Fields (TTFields) therapy is a pioneering treatment for solid tumors. Approved for use in adult patients with glioblastoma, the technology behind TTFields has the potential to provide a new line of therapy for a variety of cancers, alongside conventional surgery, radiation and chemotherapy.
Exit: IPO

Part of the Johnson & Johnson group of companies, and with a portfolio of products including the CARTO advanced imaging system, Biosense-Webster specializes in the science of diagnosing and treating cardiac arrhythmia. Working in partnership with clinical experts, the company is a world leader in the development of technologies in arrhythmia care.
Exit: Merger

InStent is was a developer and manufacturer of innovative stenting technology to support blood vessels and other passageways within the body. Producing both self-expandable and balloon stents, InStent’s products were based on a unique proprietary catheter delivery system.
Exit: Merger

Radiancy’s LHE™ (Light Heat Technology) and Thermicon™ technologies support a range of aesthetic and dermatological devices for both professional and home use. As a leading developer and manufacturer in the field of dermatology, Radiancy’s professional products offer treatment for acne, skin tightening, psoriasis and hair removal.
Exit: Merger

A world leader in the development of robotic-assisted percutaneous interventions (PCIs), Corindus Vascular Robotics is the developer of the FDA-approved CorPath® System. CorPath’s unique technology and design provides interventional cardiologists with precision control in PCI procedures from within a cockpit, preventing exposure to radiation.
Exit: IPO

A developer and manufacturer of expandable orthopedic implants, Disc-O-Tech Medical Technologies offered products and systems to support minimally invasive surgery in the treatment of the spine, hip and trauma, including the B-Twin expandable spine spacer and the Fixion Hip System.
Exit: Merger

X-Technologies’ FXminiRAIL™ was developed for use in the treatment of coronary artery disease. Designed for the treatment of de novo lesions and in-stent restenosis, this unique device could also be employed in conjunction with stenting and brachytherapy.
Exit: Merger

Spectrum Dynamics’ innovative imaging systems are based on its pioneering Broadview™ technology. Through personalized molecular imaging and unique image quality and resolution, Spectrum Dynamics’ scanning technology and accessories aim to revolutionize the field of nuclear medicine.
Exit: Merger

NovoCure’s Tumor Treating Fields (TTFields) therapy is a pioneering treatment for solid tumors. Approved for use in adult patients with glioblastoma, the technology behind TTFields has the potential to provide a new line of therapy for a variety of cancers, alongside conventional surgery, radiation and chemotherapy.
Exit: IPO

A world leader in the development of robotic-assisted percutaneous interventions (PCIs), Corindus Vascular Robotics is the developer of the FDA-approved CorPath® System. CorPath’s unique technology and design provides interventional cardiologists with precision control in PCI procedures from within a cockpit, preventing exposure to radiation.
Exit: IPO

Part of the Johnson & Johnson group of companies, and with a portfolio of products including the CARTO advanced imaging system, Biosense-Webster specializes in the science of diagnosing and treating cardiac arrhythmia. Working in partnership with clinical experts, the company is a world leader in the development of technologies in arrhythmia care.
Exit: Merger

A developer and manufacturer of expandable orthopedic implants, Disc-O-Tech Medical Technologies offered products and systems to support minimally invasive surgery in the treatment of the spine, hip and trauma, including the B-Twin expandable spine spacer and the Fixion Hip System.
Exit: Merger

InStent is was a developer and manufacturer of innovative stenting technology to support blood vessels and other passageways within the body. Producing both self-expandable and balloon stents, InStent’s products were based on a unique proprietary catheter delivery system.
Exit: Merger

X-Technologies’ FXminiRAIL™ was developed for use in the treatment of coronary artery disease. Designed for the treatment of de novo lesions and in-stent restenosis, this unique device could also be employed in conjunction with stenting and brachytherapy.
Exit: Merger

Radiancy’s LHE™ (Light Heat Technology) and Thermicon™ technologies support a range of aesthetic and dermatological devices for both professional and home use. As a leading developer and manufacturer in the field of dermatology, Radiancy’s professional products offer treatment for acne, skin tightening, psoriasis and hair removal.
Exit: Merger

Spectrum Dynamics’ innovative imaging systems are based on its pioneering Broadview™ technology. Through personalized molecular imaging and unique image quality and resolution, Spectrum Dynamics’ scanning technology and accessories aim to revolutionize the field of nuclear medicine.
Exit: Merger

Stay up to date